Hager Investment Management Services LLC Takes Position in Novo Nordisk A/S (NYSE:NVO)

Hager Investment Management Services LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 530 shares of the company’s stock, valued at approximately $46,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the third quarter valued at $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $48,000. Dunhill Financial LLC increased its holdings in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares during the last quarter. Finally, Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NVO shares. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

NVO stock opened at $85.83 on Thursday. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The firm has a market cap of $385.16 billion, a price-to-earnings ratio of 27.78, a PEG ratio of 0.93 and a beta of 0.45. The business’s fifty day simple moving average is $92.65 and its two-hundred day simple moving average is $112.19. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Analysts predict that Novo Nordisk A/S will post 3.16 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.